02/06/2026
Join Sobi and other healthcare professionals for a presentation featuring an overview of primary
hemophagocytic lymphohistiocytosis (HLH) diagnosis and treatment with Gamifant. The session will
include an in-depth look at Gamifant as an interferon gamma–blocking antibody treatment option
and a Q&A segment for additional information.1
Date:
Thursday, April 23, 2026
Time:
6:00 PM ET
Location:
Davio's Italian Steakhouse
200 Main St
King of Prussia, PA 19406
Eric Halstead, MD, PHD
Critical Care & Pediatrics
Penn State Health Children's Hospital
Hershey, PA
Sobi Contact
To register:
Steve Lewis steven.lewis@sobi.com https://sobi.hlxregister.com/
Invite code:
R52ZF3
Indication
Gamifant® (emapalumab-lzsg) is an interferon gamma (IFNγ)–blocking antibody indicated for the treatment
of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH)
with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.
Date: Thursday, April 23, 2026 Time: 6:00 PM ET Location: Davio's Italian Steakhouse 200 Main St King of Prussia, PA 19406 Eric Halstead, MD, PHD Critical Care & Pediatrics Penn State Health...